FDA expands approval of Sutent to reduce the risk of kidney cancer returning

FDA approves first adjuvant treatment for adult patients who are at a high risk of kidney cancer returning after a kidney has been removed.
Source: Food and Drug Administration - Category: American Health Source Type: news